

Accepted Manuscript

Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management

Jorge E. Cortes, M.D., Carlos A. Jimenez, M.D., Michael J. Mauro, M.D., Alex Geyer, M.D., Javier Pinilla-Ibarz, M.D., Ph.D, B. Douglas Smith, M.D.

PII: S2152-2650(16)30568-7

DOI: [10.1016/j.clml.2016.09.012](https://doi.org/10.1016/j.clml.2016.09.012)

Reference: CLML 852

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 21 April 2016

Revised Date: 31 August 2016

Accepted Date: 8 September 2016

Please cite this article as: Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD, Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management, *Clinical Lymphoma, Myeloma and Leukemia* (2016), doi: 10.1016/j.clml.2016.09.012.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management

Running title: Pleural effusion on dasatinib in CML-CP

Jorge E. Cortes, M.D.¹; Carlos A. Jimenez, M.D.¹; Michael J. Mauro, M.D.²; Alex Geyer, M.D.²; Javier Pinilla-Ibarz, M.D., Ph.D.³; and B. Douglas Smith, M.D.⁴

¹University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; ⁴Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

Correspondence:

Jorge E. Cortes, MD
Department of Leukemia
MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 0428
Houston, TX 77030
Telephone: 713-794-5783
Fax: 713-792-5224
E-mail: jcortes@mdanderson.org

Classifications: leukemia, myeloproliferative neoplasms, chronic myeloid leukemia, first-line therapy, second-line therapy, targeted therapies, toxicities

Keywords: algorithms; BCR-ABL1-targeted tyrosine kinase inhibitor; fluid retention adverse event

Article was not invited.

Abstract word count: 90

Manuscript word count: 2467 (including references within text)

Tables and Figures: 1 figure, 1 table

References: 20

Page count: 18

Funding sources for the work: Bristol-Myers Squibb

Download English Version:

<https://daneshyari.com/en/article/5582056>

Download Persian Version:

<https://daneshyari.com/article/5582056>

[Daneshyari.com](https://daneshyari.com)